Wednesday, December 16, 2009 8:31:50 PM
The study was performed at the University of Pittsburgh under the guidance of Dr. Adriana Larregina, Research Assistant Professor in the departments of Dermatology and Immunology at the University of Pittsburgh School of Medicine. The results of the study showed Homspera augmented a poorly effective vaccine against melanoma, the deadliest form of skin cancer, into a highly effective vaccine. The addition of Homspera as an adjuvant to this vaccine resulted in an increased immune response, significantly (p < 0.01) reducing the size of tumors by approximately 85% after 3 weeks, and increasing the percentage of animals surviving from 0% to 50% after 100 days (the end of the study period). Enhanced immune responses, specifically the cellular immune component, could be critical to the successful prevention and/or treatment of most cancers.
http://www.marketwire.com/press-release/Immuneregen-Biosciences-1090123.html
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM